- Home
- TSHA
as 11-15-2024 4:00pm EST
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | DALLAS |
| Market Cap: | 403.7M | IPO Year: | 2020 |
| Target Price: | $6.63 | AVG Volume (30 days): | 6.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.19 - $4.32 | Next Earning Date: | 11-13-2024 |
| Revenue: | $9,915,000 | Revenue Growth: | -30.90% |
| Revenue Growth (this year): | -44.79% | Revenue Growth (next year): | -37.45% |
Latest Taysha Gene Therapies Inc. News
TSHA Breaking Stock News: Dive into TSHA Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Taysha Gene Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Thomson Reuters StreetEvents
3 days ago
Q3 2024 Taysha Gene Therapies Inc Earnings Call
GuruFocus.com
4 days ago
Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlights: Clinical Progress and ...
Zacks
4 days ago
Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates
GlobeNewswire
4 days ago
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Simply Wall St.
6 days ago
US Penny Stocks To Watch In November 2024
GlobeNewswire
11 days ago
Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13
GlobeNewswire
16 days ago
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Compare TSHA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TSHA Taysha Gene Therapies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.